What to Expect When Mylan Reports Earnings

Health and Healthcare

Published: August 9, 2016 12:35 pm

Last Updated: January 13, 2020 4:46 am

Mylan N.V. (NASDAQ: MYL) is set to release its second-quarter financial results after the markets close on Tuesday. The consensus estimates from Thomson Reuters are calling for $1.14 in earnings per share (EPS) on $2.57 billion in revenue. Mylan posted EPS of $0.91 and $2.37 billion in revenue in the same period of last year.

This is an analyst favorite and it sports a very appealing valuation. Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals worldwide.

Like other major pharmaceutical companies, Mylan provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers, and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management and cardiovascular therapeutic areas.

Mylan had attempted a takeover of drugmaker Perrigo last year, which was fought off, and the company has since announced the purchase of Meda and recent acquisition of Renaissance. Some analysts love the company’s very attractive valuation, and trading at roughly 10 times estimated 2016 earnings per share, it clearly is cheap.

Ahead during the second quarter, a few analysts weighed in on Mylan:

Morgan Stanley reiterated a Hold rating.
JPMorgan reiterated an Overweight rating.
Goldman Sachs has a Buy rating with a $60 price target.

Excluding Tuesday’s move, Mylan has underperformed the broad markets, with the stock down 10%. Over the past 52 weeks, the stock is down 14%, but in just the last quarter the stock is up 19%.

Shares of Mylan were trading up 3% at $50.10 on Tuesday, with a consensus analyst price target of $58.06 and a 52-week trading range of $37.59 to $57.77.

ALERT: Take This Retirement Quiz Now (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.